Cymbalta Receives European Approval For The Treatment Of Generalised Anxiety Disorder

Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta(R) (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD). This approval -- the fourth for duloxetine in Europe -- was issued on 28 July following an initial positive opinion issued by the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use... [read full story]                    

Add Comment
There are also 6 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organisations, related topics, regions and companies